Cancer Data Trends 2024: Genitourinary Cancers | MDedge

Article Type

Changed

Fri, 03/22/2024 - 10:45

Display Headline

Cancer Data Trends 2024: Genitourinary Cancers

Click to view more from Cancer Data Trends 2024.

References

1. Sokolova A, Cheng H. Germline testing in prostate cancer: when and who to test. Oncology (Williston Park). 2021;35(10):645-653. doi:10.46883/ONC.2021.3510.0645

2. Tuffaha H, Edmunds K, Fairbairn D, et al. Guidelines for genetic testing in prostate cancer: a scoping review. Prostate Cancer Prostatic Dis. 2023 May 18. doi:10.1038/s41391-023-00676-0

3. National Comprehensive Cancer Network. NCCN clinical practice guidelines for prostate cancer. Version 4.2023. September 7, 2023. Accessed December 20, 2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

4. National Precision Oncology Program. PMID 26149669 (e-mail, December 13, 2023).

5. Shevach J, Lynch J, Candelieri-Surette D, et al. Racial disparities in germline testing among men with pancreas, breast and metastatic prostate cancers in two health systems. J Clin Oncol. 2023;41(16 suppl):abstract 10549. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10549

6. Velaer K, Thomas IC, Yang J, et al. Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: a laboratory wide association study (LWAS). Urol Oncol. 2022;40(1):12.e23-12.e30. doi:10.1016/j.urolonc.2021.08.011

7. Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141-148. doi:10.1016/S1470-2045(12)70559-4

8. Aguilar Palacios D, Wilson B, Michael P, et al. A novel metric for hospital quality in kidney cancer surgery: a Veterans Affairs National Health System validation of concept. Urol Pract. 2022;9(3):237-245. doi:10.1097/UPJ.0000000000000294

9. Williams SB, Janes JL, Howard LE, et al. Exposure to Agent Orange and risk of bladder cancer among US veterans. JAMA Netw Open. 2023;6(6):e2320593. doi:10.1001/jamanetworkopen.2023.20593

10. Penn T, Borza T, Liou JI, et al. Impact of Agent Orange exposure on non-muscle invasive bladder cancer outcomes. Urology. 2023;182:175-180. doi:10.1016/j.urology.2023.08.037

Author and Disclosure Information

Reviewed by Bruce Montgomery, MD
Professor
Attending Physician
Department of Medicine, Oncology
University of Washington
Fred Hutchinson Cancer Center
VA Puget Sound Health Care System
Seattle, WA

Dr. Montgomery has no relevant financial relationships to disclose.

Publications

Federal Practitioner

Topics

Genitourinary Cancer

Prostate Cancer

Author and Disclosure Information

Reviewed by Bruce Montgomery, MD
Professor
Attending Physician
Department of Medicine, Oncology
University of Washington
Fred Hutchinson Cancer Center
VA Puget Sound Health Care System
Seattle, WA

Dr. Montgomery has no relevant financial relationships to disclose.

Author and Disclosure Information

Reviewed by Bruce Montgomery, MD
Professor
Attending Physician
Department of Medicine, Oncology
University of Washington
Fred Hutchinson Cancer Center
VA Puget Sound Health Care System
Seattle, WA

Dr. Montgomery has no relevant financial relationships to disclose.

Click to view more from Cancer Data Trends 2024.

Click to view more from Cancer Data Trends 2024.

References

1. Sokolova A, Cheng H. Germline testing in prostate cancer: when and who to test. Oncology (Williston Park). 2021;35(10):645-653. doi:10.46883/ONC.2021.3510.0645

2. Tuffaha H, Edmunds K, Fairbairn D, et al. Guidelines for genetic testing in prostate cancer: a scoping review. Prostate Cancer Prostatic Dis. 2023 May 18. doi:10.1038/s41391-023-00676-0

3. National Comprehensive Cancer Network. NCCN clinical practice guidelines for prostate cancer. Version 4.2023. September 7, 2023. Accessed December 20, 2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

4. National Precision Oncology Program. PMID 26149669 (e-mail, December 13, 2023).

5. Shevach J, Lynch J, Candelieri-Surette D, et al. Racial disparities in germline testing among men with pancreas, breast and metastatic prostate cancers in two health systems. J Clin Oncol. 2023;41(16 suppl):abstract 10549. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10549

6. Velaer K, Thomas IC, Yang J, et al. Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: a laboratory wide association study (LWAS). Urol Oncol. 2022;40(1):12.e23-12.e30. doi:10.1016/j.urolonc.2021.08.011

7. Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141-148. doi:10.1016/S1470-2045(12)70559-4

8. Aguilar Palacios D, Wilson B, Michael P, et al. A novel metric for hospital quality in kidney cancer surgery: a Veterans Affairs National Health System validation of concept. Urol Pract. 2022;9(3):237-245. doi:10.1097/UPJ.0000000000000294

9. Williams SB, Janes JL, Howard LE, et al. Exposure to Agent Orange and risk of bladder cancer among US veterans. JAMA Netw Open. 2023;6(6):e2320593. doi:10.1001/jamanetworkopen.2023.20593

10. Penn T, Borza T, Liou JI, et al. Impact of Agent Orange exposure on non-muscle invasive bladder cancer outcomes. Urology. 2023;182:175-180. doi:10.1016/j.urology.2023.08.037

References

1. Sokolova A, Cheng H. Germline testing in prostate cancer: when and who to test. Oncology (Williston Park). 2021;35(10):645-653. doi:10.46883/ONC.2021.3510.0645

2. Tuffaha H, Edmunds K, Fairbairn D, et al. Guidelines for genetic testing in prostate cancer: a scoping review. Prostate Cancer Prostatic Dis. 2023 May 18. doi:10.1038/s41391-023-00676-0

3. National Comprehensive Cancer Network. NCCN clinical practice guidelines for prostate cancer. Version 4.2023. September 7, 2023. Accessed December 20, 2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

4. National Precision Oncology Program. PMID 26149669 (e-mail, December 13, 2023).

5. Shevach J, Lynch J, Candelieri-Surette D, et al. Racial disparities in germline testing among men with pancreas, breast and metastatic prostate cancers in two health systems. J Clin Oncol. 2023;41(16 suppl):abstract 10549. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10549

6. Velaer K, Thomas IC, Yang J, et al. Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: a laboratory wide association study (LWAS). Urol Oncol. 2022;40(1):12.e23-12.e30. doi:10.1016/j.urolonc.2021.08.011

7. Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141-148. doi:10.1016/S1470-2045(12)70559-4

8. Aguilar Palacios D, Wilson B, Michael P, et al. A novel metric for hospital quality in kidney cancer surgery: a Veterans Affairs National Health System validation of concept. Urol Pract. 2022;9(3):237-245. doi:10.1097/UPJ.0000000000000294

9. Williams SB, Janes JL, Howard LE, et al. Exposure to Agent Orange and risk of bladder cancer among US veterans. JAMA Netw Open. 2023;6(6):e2320593. doi:10.1001/jamanetworkopen.2023.20593

10. Penn T, Borza T, Liou JI, et al. Impact of Agent Orange exposure on non-muscle invasive bladder cancer outcomes. Urology. 2023;182:175-180. doi:10.1016/j.urology.2023.08.037

Publications

Federal Practitioner

Publications

Federal Practitioner

Topics

Genitourinary Cancer

Prostate Cancer

Article Type

Display Headline

Cancer Data Trends 2024: Genitourinary Cancers

Display Headline

Cancer Data Trends 2024: Genitourinary Cancers

Disallow All Ads

Content Gating

No Gating (article Unlocked/Free)

Alternative CME

Disqus Comments

Default

Eyebrow Default

Slideshow

Un-Gate On Date

Thu, 03/14/2024 - 14:30

Consolidated Pubs: Do Not Show Source Publication Logo

Use ProPublica

CFC Schedule Remove Status

Thu, 03/14/2024 - 14:30

Conference Recap Checkbox

Not Conference Recap

Clinical Edge

Display the Slideshow in this Article

Slide

Gating Strategy

No Gating

Medscape Article

Display survey writer

Reuters content

Disable Inline Native ads

WebMD Article

Slide Media